Data gathered: December 9
AI Stock Analysis - Novo Nordisk (NVO)
Analysis generated December 9, 2024. Powered by Chat GPT.
Novo Nordisk is a leading global healthcare company headquartered in Denmark, known for its innovative products in diabetes care, hemophilia treatment, hormone replacement therapy, and growth hormone therapy. With a strong emphasis on research and development, Novo Nordisk holds a significant market position and continues to innovate in therapeutic areas to improve the lives of patients worldwide.
Stock Alerts - Novo Nordisk (NVO)
 |
Novo Nordisk | December 6 Reddit mentions are up by 936% in the last 24h. |
|
Novo Nordisk | November 22 Reddit mentions are up by 153% in the last 24h. |
|
Novo Nordisk | November 15 Michael McCaul (member of U.S. congress) is buying shares |
|
Novo Nordisk | November 10 AI Score is up by 20.2% in the last couple of days. |
Alternative Data for Novo Nordisk
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 6 | Sign up | Sign up | Sign up |
| Sentiment | 83 | Sign up | Sign up | Sign up |
| Webpage traffic | 846,000 | Sign up | Sign up | Sign up |
| Employee Rating | 86 | Sign up | Sign up | Sign up |
| Google Trends | 18 | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 51,494 | Sign up | Sign up | Sign up |
| Facebook Followers | 724,446 | Sign up | Sign up | Sign up |
| Instagram Followers | 131,826 | Sign up | Sign up | Sign up |
| Reddit Mentions | 4 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 11 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 11,641 | Sign up | Sign up | Sign up |
| Twitter Followers | 49,814 | Sign up | Sign up | Sign up |
| Twitter Mentions | 53 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 36,700 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Lobbying Cost | $323,000 | Sign up | Sign up | Sign up |
| Business Outlook | 86 | Sign up | Sign up | Sign up |
| Linkedin Employees | 61,497 | Sign up | Sign up | Sign up |
About Novo Nordisk
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents.
| Price | $111.08 |
| Target Price | Sign up |
| Volume | 4,910,000 |
| Market Cap | $473B |
| Year Range | $99.81 - $146.35 |
| Dividend Yield | 1.42% |
| PE Ratio | 34.03 |
| Analyst Rating | 67% buy |
| Industry | Drug Manufacturers |
In the news
Novo Nordisk A/S - share repurchase programmeDecember 9 - GlobeNewswire |
|
The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo HoldingsDecember 6 - GlobeNewswire |
|
 |
Top Research Reports for Berkshire Hathaway, Exxon Mobil & Novo NordiskDecember 6 - Yahoo |
 |
Charles Schwab Investment Management Inc. Acquires 28,988 Shares of Novo Nordisk A/S (NYSE:NVO)December 6 - ETF Daily News |
 |
Novo Nordisk slashes U.S. list prices for insulin meds Tresiba, FiaspDecember 5 - Seeking Alpha |
 |
Novo Nordisk (NVO) Stock Moves -0.14%: What You Should KnowDecember 5 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 71.3B | 11.3B | 60B | 27.3B | 37.4B | 0.900 |
| Q2 '24 | 68.1B | 10.3B | 57.8B | 20.1B | 34.8B | 0.660 |
| Q1 '24 | 65.3B | 9.92B | 55.4B | 25.4B | 35.3B | 0.830 |
| Q4 '23 | 65.9B | 10B | 55.8B | 22B | 28.5B | 0.710 |
| Q3 '23 | 58.7B | 9.71B | 49B | 22.5B | 29.4B | 0.730 |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$149.6 0.2% | 56 |
 |
Eli Lilly and CompanyLLY |
$803.58 2.8% | 64 |
 |
PfizerPFE |
$26.1 1.4% | 46 |
 |
AstrazenecaAZN |
$68.58 0.6% | 66 |
 |
AbbVieABBV |
$176.57 0.2% | 65 |
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Michael McCaul |
Nov 14, 24 | Buy | $15K - $50K |
| John James |
Sep 2, 24 | Buy | $1K - $15K |
| Michael McCaul |
Jun 20, 24 | Buy | $15K - $50K |
Read more about Novo Nordisk (NVO) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Novo Nordisk?
The Market Cap of Novo Nordisk is $473B.
What is Novo Nordisk's PE Ratio?
As of today, Novo Nordisk's PE (Price to Earnings) ratio is 34.03.
What is the current stock price of Novo Nordisk?
Currently, the price of one share of Novo Nordisk stock is $111.08.
How can I analyze the NVO stock price chart for investment decisions?
The NVO stock price chart above provides a comprehensive visual representation of Novo Nordisk's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Novo Nordisk shares. Our platform offers an up-to-date NVO stock price chart, along with technical data analysis and alternative data insights.
Does NVO offer dividends to its shareholders?
Yes, Novo Nordisk (NVO) offers dividends to its shareholders, with a dividend yield of 1.42%. This dividend yield represents Novo Nordisk's commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Novo Nordisk in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
What are some of the similar stocks of Novo Nordisk?
Some of the similar stocks of Novo Nordisk are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
.